We studied the effects of SNK-411, a new 5-pyrimidinol derivative, on serum cytokine profile of C57Bl/6 mice with Lewis lung carcinoma. The compound was injected intraperitoneally in doses of 25 and 50 mg/kg. A significant (by 3.5 times) increase in serum IL-4 content was detected in mice with tumors on day 9 of tumor development. In mice receiving SNK-411 in doses of 25 and 50 mg/kg, IL-4 content significantly decreased (by 4.0 and 3.6 times) on days 2–8 of carcinoma development; IL-2 content decreased by 1.4 and 1.2 times and IL-6 content decreased by 2.7 and 1.6 times, respectively, in comparison with control mice with tumors. Injections of SNK-411 in the same doses on days 8–15 of carcinoma development led to a significant decrease in IL-4 levels (by 2.2 and 4.5 times, respectively, in comparison with control mice with tumors) and did not affect serum levels of other cytokines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
A. E. Berezhnoi, N. V. Gnuchev, G. P. Georgiev, et al., Vopr. Onkol., 54, No. 6, 669–683 (2008).
A. V. Lichtenstein, Biokhimiya, 79, No. 5, 493–500 (2014).
V. I. Novikov, A. A. Vlasov, V. I. Karandashov, et al., Preparations. Methods, and Protocols of Tumor Immunotherapy [in Russian], Moscow (2006), pp. 10–14.
S. B. Seredenin, S. V. Nikitin, L. P. Konovalenko, et al., Patent RF No. 2518889. 5-Pyrimidinol Derivative with Antitumor Activity, Byull., No. 16, June 10, 2014.
E. M. Treshchalina, O. S. Zhukova, G. K. Gerasimova, et al., Manual for Preclinical Studies of Drugs [in Russian], Ed. A. N. Mironov, Moscow (2012), pp. 642–656.
B. H. Al-Ghurabi, J. Fac. Med. Bagdhdad, 51, No. 3, 300–303 (2009).
G. Dranoff, Nat. Rev. Cancer, 4, No. 1, 11–22 (2004).
G. Germano, P. Allavena, and A. Mantovani, Cytokine, 43, No. 3, 374–379 (2008).
M. Krzystek-Korpacka, D. Diakowska, B. Kapturkiewicz, et al., Cancer Lett., 337, No. 1, 107–114 (2013).
Z. Li, J. Jiang, Z. Wang, et al., Cancer Res., 68, No. 21, 8687–8694 (2008).
Z. Li, L. Chen, and Z. Qin, Cell. Mol. Immunol., 6, No. 6, 415–422 (2009).
T. M. Long and J. P. Raufman, Gastrointestinal Cancer: Targets and Therapy, 1, 27–39 (2011).
O. Prokopchuk, Y. Liu, D. Henne-Bruns, and M. Kornmann, Brit. J. Cancer, 92, No. 5, 921–928 (2005).
H. Roca, M. J. Craig, C. Ying, et al., J. Cell. Biochem., 113, No. 5, 1569–1580 (2012).
K. Taniguchi and M. Karin, Sem. Immunol., 26, No. 1, 54–74 (2014).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 160, No. 10, pp. 488–491, October, 2015
Rights and permissions
About this article
Cite this article
Kuznetsova, O.S., Tallerova, A.V., Nikitin, S.V. et al. Effects of 5-Pyrimidinol Derivative SNK-41 on Cytokine Profile of Mice with Lewis Lung Carcinoma. Bull Exp Biol Med 160, 483–485 (2016). https://doi.org/10.1007/s10517-016-3202-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-016-3202-z